Showing papers by "Richard J. Ulevitch published in 1986"

Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum.

Abstract: This report describes the purification of an acute phase reactant from acute phase rabbit serum, which endows normal serum with the properties of acute phase serum, insofar as LPS is concerned. The acute phase reactant is referred to as LPS-binding protein, or LBP. LBP was purified approximately 2,000-fold by chromatography of acute phase serum on Bio-Rex 70 and Mono-Q resins. The resulting preparation consisted of two glycoproteins having molecular weights of 60,500 and 58,000; the two were obtained in a variable ratio, usually near 10:1, respectively. After separation by SDS-PAGE, the N-terminal 36 amino acid sequences of the two proteins were identical. From the N-terminal sequence, as well as other properties of LBP, LBP appears to be unrelated to any known acute phase reactants. The direct interaction of LPS and LBP was inferred from two types of evidence: first, immunoprecipitation of [3H]LPS from APRS by anti-LBP sera; and second, by the 125I-labeling of LBP when APRS-containing 125I-labeled 2-(p-azidosalicylamido)ethyl 1,3'-dithiopropionyl-LPS was photolysed. The data presented here support the concept that the 60-kD glycoprotein we have termed LBP is a newly recognized acute phase reactant that may modulate the biochemical and biologic properties of LPS in vivo.

Partial restoration of the lipopolysaccharide-induced proliferative response in splenic B cells from C3H/HeJ mice.

Abstract: C3H/HeJ mice are hyporesponsive to the biologic effects of bacterial lipopolysaccharide (LPS), and their splenic B cells do not proliferate after exposure to LPS. The molecular basis of this hyporesponsiveness is unknown but it may result from defective membrane signal transduction after LPS binding. To examine this possibility, we added bioactive compounds in combination with LPS to C3H/HeJ B cell cultures in order to bypass the putative defect. The addition of PMA, monensin, or ionomycin, either alone or in combination, had no effect on C3H/HeJ B cell responses to LPS. In contrast, the addition of trypsin together with LPS resulted in a partial restoration of the proliferative response in C3H/HeJ splenic B lymphocytes. The maximal C3H/HeJ B cell response varied from 25 to 60% of the C3Heb/FeJ (LPS responder) B cell response. The trypsin-mediated enhancement of the LPS response was abrogated by pretreatment of the trypsin with the trypsin inhibitors DFP or TLCK. Pretreatment of the LPS with polymyxin B, which blocks lipid A-dependent reactions, also abrogated the trypsin effect. Because the C3H/HeJ B cell responds to all other B cell mitogens, we suggest that the defect is in an LPS-specific step and that the action of trypsin results in the restoration of the missing signal. At the present time the identity of this signal is not known, but the experiments described in this report provide a unique model to elucidate the basis of LPS hyporesponsiveness in splenic B cells from C3H/HeJ mice.

Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods

Abstract: Composition therapeutique contenant une glycoproteine pour le traitement d'un hote animal, procedes, polypeptides et anticorps relatifs a ladite glycoproteine. La composition contient une quantite efficace d'une glycoproteine, laquelle (a) est presente dans un serum pendant la phase aigue, mais est essentiellement absente du serum normal; (b) se lie au lipopolysaccharide secrete par les bacteries gram-negatives in vitro dans le serum de l'animal traite; (c) retarde in vitro la liaison du lipopolysaccharide a une lipoproteine de densite elevee presente dans le serum normal de l'hote animal.